SATB2 and colorectal carcinoma: These findings delineate SATB2 as a worthwhile immunohistochemical biomarker in CRC that can identify especially aggressive cancers in these high-risk subgroups of CRC and delivers valuable additional prognostic information in addition to standard histomorphological factors and UICC staging.